Navigation Links
Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
Date:11/10/2008

of $6.4 million in the nine months ended September 30, 2008 compared with $4.3 million for the same period in 2007. Pfizer will fund 60 percent of U.S. Dimebon-related development expenses incurred on or after October 21, 2008, the closing date of our collaboration agreement, and 100 percent of ex-U.S. Dimebon-related development expenses. Thus, we expect that Dimebon-related operating expenses after cost sharing payments from Pfizer will decrease in the fourth quarter of 2008 compared with the third quarter. We intend to provide full-year 2009 financial guidance in the first quarter of 2009.

Cash and cash equivalents at September 30, 2008 totaled $20.4 million, compared with $43.3 million at December 31, 2007. On October 27, 2008, Medivation received its $225 million up-front payment from Pfizer pursuant to the Dimebon collaboration agreement. Even after taking into account the expanded Dimebon development being undertaken with Pfizer, the upfront payment and development milestone payments Medivation is eligible to receive under the Pfizer agreement significantly exceed the Company's share of presently budgeted development and pre-launch commercialization costs for Dimebon.

Conference Call Information

To participate in today's live call beginning at 4:30 p.m. Eastern Time by telephone, please call 877-340-7912 from the U.S. or +719-325-4872 internationally. In addition, the live conference call is being webcast and can be accessed on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at http://www.medivation.com. A replay also will be available for 30 days following the live call.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these di
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
2. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
3. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
4. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
5. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
6. Medivation Announces Participation in Upcoming Conferences
7. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
8. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
9. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
10. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
11. Medivation Announces Senior Management Promotions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Earlier this year in a June 24 international ... Adult Stem Cell Technology Center, LLC ( ASCTC ) ... unique property of adult tissue stem cells. His ... the Past, Important for the Future,” embodied the essence ... the address at the 4th World Congress on Cell ...
(Date:12/24/2014)... December 23, 2014 According to Ross Selinger, ... Affiliate of ITRA Global, the national office market continues to ... This is evidenced by the third quarter’s surprising 3.9% ... Low energy costs have held inflation down and the ... is the housing market remaining soft. , This solid economic ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 The report ... at 19.7% by 2019. It also provides a carefully ... strategies and challenges for the market. , Full Copy ... the report, the global market for cell expansion will ... future. It expects this growth to be driven by ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 23, 2014 /PRNewswire/ ... solutions company focused on gynecologic disease, announced today ... W. Schuler , Birchview Fund LLC and several ... million of unregistered shares of Vermillion,s common stock ... common stock in a private placement.  ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
... , ... ... ... ...
... , ... symposium to unveil study aimed at ensuring global food security and sustainability. , ... Washington (PRWEB) -- On ... sustainably double agricultural output and improve storage and distribution to eliminate the global productivity ...
... ... ... ... ...
Cached Biology Technology:Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 2Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 3Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 4Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 5Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 6Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 7Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 8Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 9Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 10Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 11Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 12Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 13Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 14Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 15Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 16Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 17Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 18Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 19Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 20Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 21Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 22Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 23Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 24Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 25Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 26Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 27Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 28Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 29Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 30Gloabl Harvest Initiative: Taking Down Fences To Meet Future Needs 2Gloabl Harvest Initiative: Taking Down Fences To Meet Future Needs 3Tianyin Pharmaceutical Co., Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing on March 9 2Tianyin Pharmaceutical Co., Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing on March 9 3Tianyin Pharmaceutical Co., Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing on March 9 4Tianyin Pharmaceutical Co., Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing on March 9 5
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a ... $2.3 million in Series A1 funding led by UK-based ... also participated in the investment round. "We ... healthcare community adopts next-generation sequencing and seeks new approaches ... Reid Robison , MD MBA, and CEO of ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... physics now becomes easier with the formal launch of ... from the American Physical Society. Physics will highlight and ... publications of Physical Review Letters and the ... will keep readers apprised of important new articles as ...
... information, as detectives, historians and identity thieves well ... treasures, University of Delaware researchers have found. ... UD,s Delaware Biotechnology Institute analyzed the cellular waste ... discovered formerly hidden relationships between genes and the ...
... of Oregon,s Climate Leadership Initiative, the need to address ... Bob Doppelt says in his new book requires a ... The 240-page book published by London-based Earthscan Publications Ltd. ... private sector, but its content is accessible to "anyone ...
Cached Biology News:American Physical Society announces Physics, a new, free, online publication 2Using novel tool, UD researchers dig through cell 'trash' and find treasure 2Using novel tool, UD researchers dig through cell 'trash' and find treasure 3'No time to lose' to start thinking sustainability 2
... Disposable. Virgin, optically clear polystyrene ... and alphanumeric coordinates for cell counting. ... number is a new product number, ... number. If showing no availability yet, ...
... CellBIND surface is produced by a ... more hydrophilic surface giving more consistent, ... and yields. CellBIND enhances cell attachment ... reduced serum or serum-free medium. • ...
Cell Culture Flask, 75 cm, treated polystyrene...
... Disposable. Virgin, optically clear polystyrene ... and alphanumeric coordinates for cell counting. ... number is a new product number, ... number. If showing no availability yet, ...
Biology Products: